- CD59 antibody uses novel approach to "de-cloak" cancers -
TORONTO, Oct. 25 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced that new findings have been presented from its Trop-2 and CD59 antibody programs. ARIUS scientists will discuss the Company's Trop-2 and CD59 abstracts at the AACR press conference today at 9:30 a.m. PT.
"Both our Trop-2 and CD59 antibody programs have demonstrated novel approaches in treating cancer. Our Trop-2 antibody is a novel target and has been linked to aggressive cancers in the scientific literature, while our CD59 program has demonstrated the ability to foil a cancer cell's ability to evade the immune system," said Dr. David Young, President and CEO. "These programs, in addition to our CD44 cancer stem cell program, were generated through our proprietary drug discovery technology, FunctionFIRST(TM), which is inherently designed to produce novel antibodies and identify unique cancer targets."
Trop-2 Proffered Paper Presentation
ARIUS' Trop-2 targeting antibody has demonstrated a significant anti-tumor effect in animal models of human pancreatic cancer, inhibiting tumor growth by up to 100 percent. Subsequent testing showed efficacy in animal models of breast, colon and prostate cancers. The antibody compared favorably with Taxotere in prostate cancer model and has also shown the ability to be highly potent at low-dose concentrations.
Additional information can be found at the AACR-NCI-EORTC 2007
International Conference on Molecular Targets and Cancer Therapeutics in
San Francisco at the following location and time: AR47A6.4.2, a functional
naked monoclonal antibody targeting Trop-2, demonstrates in vivo efficacy
in human pancreatic, colon, breast and prostate cancer models. Proffered
Paper Session 3, Thursday, October 25, 2007 from 5:15 - 5:30 p.m. in the
Third Floor Ballroom a
|SOURCE ARIUS Research Inc.|
Copyright©2007 PR Newswire.
All rights reserved